The goal is to see this potentially ground breaking novel medicine impacting patients lives without delay.
In order to achieve this objective, E3Bio has been established as a semi-virtual, asset centric organisation. The company will leverage leading scientific expertise with a management team of experienced drug developers.
What is a virtual company?
A virtual biotech company maintains minimal infrastructure by using partnerships with expert service providers to advance the development of its assets. With proper leadership and management, out-sourcing drug development to the most appropriate experts can speed up progress, improve outcomes and reduce costs. E3Bio benefits from the expertise of the out-sourced drug development firms it works with, including RxCelerate, SYNthesis Med Chem, XenoGesis and Total Scientific.
What is an asset-centric company?
The term asset-centric is used to refer to biotech companies developing a single asset. This ensures the entire focus of the management team and all the available resources are directed towards the successful development of that asset. For E3Bio, the single asset will be a small molecule stimulator of cell debris clearance.